Leflunomide: Difference between revisions
imported>Caesar Schinas m (Bot: Replacing medical templates with CZMed) |
mNo edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
{{Image|Leflunomide structure.jpg|right|150px|Leflunomide.}} | |||
'''Leflunomide''', with IUPAC name 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide and chemical formula C<sub>12</sub>H<sub>9</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>, also called leflunomidum and lefunomide, is a pyrimidine synthesis inhibitor belonging to the [[DMARD]] (disease-modifying antirheumatic drug) class of drugs used to treat [[rheumatoid arthritis]] (RA). Activated T cells, which are increased in patients with RA, are dependent on de novo pyrimidine synthesis and will thus be more affected by leflunomide's inhibition of [[dihydroorotate dehydrogenase]] than other cell types that use the salvage pathway of pyrimidine synthesis. It is sold under the brand name '''Arava'''. | '''Leflunomide''', with IUPAC name 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide and chemical formula C<sub>12</sub>H<sub>9</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>, also called leflunomidum and lefunomide, is a pyrimidine synthesis inhibitor belonging to the [[DMARD]] (disease-modifying antirheumatic drug) class of drugs used to treat [[rheumatoid arthritis]] (RA). Activated T cells, which are increased in patients with RA, are dependent on de novo pyrimidine synthesis and will thus be more affected by leflunomide's inhibition of [[dihydroorotate dehydrogenase]] than other cell types that use the salvage pathway of pyrimidine synthesis. It is sold under the brand name '''Arava'''. | ||
| Line 8: | Line 8: | ||
== External Links == | == External Links == | ||
{{CZMed}} | {{CZMed}}[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 06:00, 11 September 2024
Leflunomide, with IUPAC name 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide and chemical formula C12H9F3N2O2, also called leflunomidum and lefunomide, is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs used to treat rheumatoid arthritis (RA). Activated T cells, which are increased in patients with RA, are dependent on de novo pyrimidine synthesis and will thus be more affected by leflunomide's inhibition of dihydroorotate dehydrogenase than other cell types that use the salvage pathway of pyrimidine synthesis. It is sold under the brand name Arava.
drug interactions
Leflunomide increases the anticoagulation effects of anisindione, acenocoumarol, dicumarol and warfarin. Rifampin increases the effect of leflunomide.
External Links
The most up-to-date information about Leflunomide and other drugs can be found at the following sites.
- Leflunomide - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Leflunomide - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Leflunomide - Detailed information from DrugBank.